Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Topics Community

Article

Dose-Dependent Effect of Tumor Mutation Burden on Cancer Prognosis Following Immune Checkpoint Blockade: Causal Implications.

Frontiers in immunology - 1 Jan 2022

Zheng Ming

Abstract excerpt

No abstract is available from the source.

Topics

Biomarkers, Tumor
Humans
Immune Checkpoint Inhibitors
Mutation
Neoplasms
Prognosis

Source

Open in PubMed Open full text

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 35720282
DOI: 10.3389/fimmu.2022.853300
PMCID: PMC9203856

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dose-Dependent Effect of Tumor Mutation Burden on Cancer Prognosis Following Immune Checkpoint Blockade: Causal Implications.PMID 35720282Read ↗

Tumor Mutation Burden and Cancer Treatment.Semantic proximity Read ↗

Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinicSemantic proximity Read ↗

The status of tumor mutational burden and immunotherapySemantic proximity Read ↗

The Spectrum of Benefit from Checkpoint Blockade in Hypermutated TumorsSemantic proximity Read ↗

Tumor mutational load predicts survival after immunotherapy across multiple cancer typesSemantic proximity Read ↗

Using a Recently Approved Tumor Mutational Burden Biomarker to Stratify Patients for Immunotherapy May Introduce a Sex Bias.Semantic proximity Read ↗

Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers.Semantic proximity Read ↗

Beyond Tumor PD-L1: Emerging Genomic Biomarkers for Checkpoint Inhibitor ImmunotherapySemantic proximity Read ↗

High Tumor Mutational Burden Correlates with Longer Survival in Immunotherapy-Naïve Patients with Diverse CancersSemantic proximity Read ↗

The association between tumor mutational burden and prognosis is dependent on treatment context.Semantic proximity Read ↗

Integrated profile of tumor stage and mutational burden predicts disparate clinical responses to immune checkpoint inhibitors: A risk-benefit study.Semantic proximity Read ↗

Tumor mutation burden to tumor burden ratio and prediction of clinical benefit of anti-PD-1/PD-L1 immunotherapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.